Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis
Background Hepatitis C diagnosis could be a gateway to behavioral change and subsequent decline in transmission among people who inject drugs (PWIDs). We assessed the association between the social determinants of PWID, their risk behaviors and hepatitis C testing. Methods We searched for studies in...
Gespeichert in:
Veröffentlicht in: | Substance abuse treatment, prevention and policy prevention and policy, 2020-08, Vol.15 (1), p.1-16, Article 64 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 16 |
---|---|
container_issue | 1 |
container_start_page | 1 |
container_title | Substance abuse treatment, prevention and policy |
container_volume | 15 |
creator | Karimi, Salah Eddin Bayani, Azadeh Higgs, Peter Bayat, Amir-Hossein Hemmat, Morteza Ahounbar, Elahe Armoon, Bahram Fakhri, Yadolah |
description | Background Hepatitis C diagnosis could be a gateway to behavioral change and subsequent decline in transmission among people who inject drugs (PWIDs). We assessed the association between the social determinants of PWID, their risk behaviors and hepatitis C testing. Methods We searched for studies in English published before May 1, 2020, on PubMed, Scopus, Cochrane, and Web of Science to identify primary studies on the factors associated with hepatitis C virus (HCV) testing among PWID. After reviewing for study duplicates, the full-text of selected articles were assessed for eligibility using Population, Intervention, Comparator, Outcomes (PICO) criteria. i) population: individuals who report injecting drugs; ii) intervention: HCV testing in the past year; iii) comparator: PWIDs who did not have an HCV test; iv) outcome: HCV testing among PWIDs and v) study type: cross-sectional, cohort, and case-control studies. Two independent reviewers (author BA and AB) chose the references in a two-phased monitoring process. The authors gathered data from selected papers, including the surname of the first author, publication date, participant demographic data (age, sex, and level of education) and other characteristics like previous HCV testing, past treatment attempts, duration of injecting drug use and condomless sex. We used fixed and random-effects meta-analysis models to estimate the pooled prevalence, pooled odds ratio (OR), and 95% confidence intervals. The data were analyzed using Stata 12.0 software. Results After a detailed assessment of over 12,000 articles, a total of 16 studies containing 38,952 participants met the eligibility criteria. Our findings showed a pooled prevalence rate of 61.01% (95% CI, 34.65-84.32%) for recent HCV testing among PWIDs. Being female (OR = 1.69, 95%CI = 1.13, 2.26), aged > 30 years, (OR = 2.61, 95%CI = 1.66-3.56) having past treatment attempt (OR = 2.24, 95%CI = 1.80-2.68), and reporting a previous test (OR = 2.03, 95%CI = 1.23-2.82). were significantly associated with having a recent HCV test.,,. Finding of present study was that unprotected sex had a negative association with HCV testing. Those PWIDs who had unprotected sex were 0.56 times less likely to have completed HCV testing during last year (OR = 0.56, 95%CI = 0.33-0.78). Conclusion Prevention programs that address age > 30 years, being female, past treatment attempt, previous testing of safe sexual practices, are strongly recommended to prioritize HCV risk reduction |
doi_str_mv | 10.1186/s13011-020-00306-1 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7445934</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A634935973</galeid><doaj_id>oai_doaj_org_article_5b69f769f685480cbad4f2a0bcbc1979</doaj_id><sourcerecordid>A634935973</sourcerecordid><originalsourceid>FETCH-LOGICAL-c574t-eb4cf2cb67dcdf6461cabc61a164a616ce1f16a816258426f0de6d370ae07b553</originalsourceid><addsrcrecordid>eNqNUk1v1DAQjRCIlsIf4GSJE0IpduLYCQekagV0pSIQX-JmTZxJ4iWJt7azy9754Xi7VWElDtjyh-z33tgzL0meMnrOWCleepZTxlKa0ZTSnIqU3UtOmeQyLSr5_f5f-5PkkfcrSjmvqvJhcpJnZc4YlafJr48ONzDgpJHA1JDedD1xxv8gNfawMXZ2noD3VhsI2JCtCT25XHwjAX0wU0dgtHFeo10PSLa9JWZaoQ6kcXPnXxEgfucDjhCMJjGUwe1NnPcYIIUJhp03_nHyoIXB45Pb9Sz5-vbNl8VlevXh3XJxcZXqQvKQYs11m-layEY3reCCaai1YMAEB8GERtYyASUTWVHyTLS0QdHkkgJSWRdFfpYsD7qNhZVaOzOC2ykLRt0cWNcpcPGhA6qiFlUr4xBlwUuqa2h4mwGtda1ZJauo9fqgtZ7rERuNU3AwHIke30ymV53dKMl5UeU8Cjy7FXD2eo7ZVKuY7JgRrzLOORVZWdE_qC4WSZmptVFMj8ZrdSFyXuWxvHlEnf8DFXuDo9F2wtbE8yPC8yNCxAT8GTqYvVfLz5-OsdkBq5313mF790lG1d6I6mBEFY2oboyoWCS9OJC2WNvWa7N32B2RUloIyWhJ920fovx_9MKE6CY7Lew8hfw3Hx_wqA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2444062890</pqid></control><display><type>article</type><title>Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis</title><source>DOAJ Directory of Open Access Journals</source><source>SpringerNature Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Web of Science - Social Sciences Citation Index – 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Springer Nature OA/Free Journals</source><creator>Karimi, Salah Eddin ; Bayani, Azadeh ; Higgs, Peter ; Bayat, Amir-Hossein ; Hemmat, Morteza ; Ahounbar, Elahe ; Armoon, Bahram ; Fakhri, Yadolah</creator><creatorcontrib>Karimi, Salah Eddin ; Bayani, Azadeh ; Higgs, Peter ; Bayat, Amir-Hossein ; Hemmat, Morteza ; Ahounbar, Elahe ; Armoon, Bahram ; Fakhri, Yadolah</creatorcontrib><description>Background Hepatitis C diagnosis could be a gateway to behavioral change and subsequent decline in transmission among people who inject drugs (PWIDs). We assessed the association between the social determinants of PWID, their risk behaviors and hepatitis C testing. Methods We searched for studies in English published before May 1, 2020, on PubMed, Scopus, Cochrane, and Web of Science to identify primary studies on the factors associated with hepatitis C virus (HCV) testing among PWID. After reviewing for study duplicates, the full-text of selected articles were assessed for eligibility using Population, Intervention, Comparator, Outcomes (PICO) criteria. i) population: individuals who report injecting drugs; ii) intervention: HCV testing in the past year; iii) comparator: PWIDs who did not have an HCV test; iv) outcome: HCV testing among PWIDs and v) study type: cross-sectional, cohort, and case-control studies. Two independent reviewers (author BA and AB) chose the references in a two-phased monitoring process. The authors gathered data from selected papers, including the surname of the first author, publication date, participant demographic data (age, sex, and level of education) and other characteristics like previous HCV testing, past treatment attempts, duration of injecting drug use and condomless sex. We used fixed and random-effects meta-analysis models to estimate the pooled prevalence, pooled odds ratio (OR), and 95% confidence intervals. The data were analyzed using Stata 12.0 software. Results After a detailed assessment of over 12,000 articles, a total of 16 studies containing 38,952 participants met the eligibility criteria. Our findings showed a pooled prevalence rate of 61.01% (95% CI, 34.65-84.32%) for recent HCV testing among PWIDs. Being female (OR = 1.69, 95%CI = 1.13, 2.26), aged > 30 years, (OR = 2.61, 95%CI = 1.66-3.56) having past treatment attempt (OR = 2.24, 95%CI = 1.80-2.68), and reporting a previous test (OR = 2.03, 95%CI = 1.23-2.82). were significantly associated with having a recent HCV test.,,. Finding of present study was that unprotected sex had a negative association with HCV testing. Those PWIDs who had unprotected sex were 0.56 times less likely to have completed HCV testing during last year (OR = 0.56, 95%CI = 0.33-0.78). Conclusion Prevention programs that address age > 30 years, being female, past treatment attempt, previous testing of safe sexual practices, are strongly recommended to prioritize HCV risk reduction strategies.</description><identifier>ISSN: 1747-597X</identifier><identifier>EISSN: 1747-597X</identifier><identifier>DOI: 10.1186/s13011-020-00306-1</identifier><identifier>PMID: 32831107</identifier><language>eng</language><publisher>LONDON: Springer Nature</publisher><subject>Agreements ; Confidence intervals ; Criminalization ; Drug use ; Drugs ; Hepatitis C ; Hepatitis C virus ; Infections ; Life Sciences & Biomedicine ; Meta-analysis ; Past treatment attempt ; Previous testing ; Review ; Science & Technology ; Sexual behavior ; Social determinants ; Stigma ; Substance Abuse ; Systematic review ; Unprotected sex ; Variables</subject><ispartof>Substance abuse treatment, prevention and policy, 2020-08, Vol.15 (1), p.1-16, Article 64</ispartof><rights>COPYRIGHT 2020 BioMed Central Ltd.</rights><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>19</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000567108000003</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c574t-eb4cf2cb67dcdf6461cabc61a164a616ce1f16a816258426f0de6d370ae07b553</citedby><cites>FETCH-LOGICAL-c574t-eb4cf2cb67dcdf6461cabc61a164a616ce1f16a816258426f0de6d370ae07b553</cites><orcidid>0000-0003-3564-1791 ; 0000-0002-3579-7641 ; 0000-0001-5467-9889</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445934/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445934/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2115,27929,27930,28254,53796,53798</link.rule.ids></links><search><creatorcontrib>Karimi, Salah Eddin</creatorcontrib><creatorcontrib>Bayani, Azadeh</creatorcontrib><creatorcontrib>Higgs, Peter</creatorcontrib><creatorcontrib>Bayat, Amir-Hossein</creatorcontrib><creatorcontrib>Hemmat, Morteza</creatorcontrib><creatorcontrib>Ahounbar, Elahe</creatorcontrib><creatorcontrib>Armoon, Bahram</creatorcontrib><creatorcontrib>Fakhri, Yadolah</creatorcontrib><title>Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis</title><title>Substance abuse treatment, prevention and policy</title><addtitle>SUBST ABUSE TREAT PR</addtitle><description>Background Hepatitis C diagnosis could be a gateway to behavioral change and subsequent decline in transmission among people who inject drugs (PWIDs). We assessed the association between the social determinants of PWID, their risk behaviors and hepatitis C testing. Methods We searched for studies in English published before May 1, 2020, on PubMed, Scopus, Cochrane, and Web of Science to identify primary studies on the factors associated with hepatitis C virus (HCV) testing among PWID. After reviewing for study duplicates, the full-text of selected articles were assessed for eligibility using Population, Intervention, Comparator, Outcomes (PICO) criteria. i) population: individuals who report injecting drugs; ii) intervention: HCV testing in the past year; iii) comparator: PWIDs who did not have an HCV test; iv) outcome: HCV testing among PWIDs and v) study type: cross-sectional, cohort, and case-control studies. Two independent reviewers (author BA and AB) chose the references in a two-phased monitoring process. The authors gathered data from selected papers, including the surname of the first author, publication date, participant demographic data (age, sex, and level of education) and other characteristics like previous HCV testing, past treatment attempts, duration of injecting drug use and condomless sex. We used fixed and random-effects meta-analysis models to estimate the pooled prevalence, pooled odds ratio (OR), and 95% confidence intervals. The data were analyzed using Stata 12.0 software. Results After a detailed assessment of over 12,000 articles, a total of 16 studies containing 38,952 participants met the eligibility criteria. Our findings showed a pooled prevalence rate of 61.01% (95% CI, 34.65-84.32%) for recent HCV testing among PWIDs. Being female (OR = 1.69, 95%CI = 1.13, 2.26), aged > 30 years, (OR = 2.61, 95%CI = 1.66-3.56) having past treatment attempt (OR = 2.24, 95%CI = 1.80-2.68), and reporting a previous test (OR = 2.03, 95%CI = 1.23-2.82). were significantly associated with having a recent HCV test.,,. Finding of present study was that unprotected sex had a negative association with HCV testing. Those PWIDs who had unprotected sex were 0.56 times less likely to have completed HCV testing during last year (OR = 0.56, 95%CI = 0.33-0.78). Conclusion Prevention programs that address age > 30 years, being female, past treatment attempt, previous testing of safe sexual practices, are strongly recommended to prioritize HCV risk reduction strategies.</description><subject>Agreements</subject><subject>Confidence intervals</subject><subject>Criminalization</subject><subject>Drug use</subject><subject>Drugs</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Infections</subject><subject>Life Sciences & Biomedicine</subject><subject>Meta-analysis</subject><subject>Past treatment attempt</subject><subject>Previous testing</subject><subject>Review</subject><subject>Science & Technology</subject><subject>Sexual behavior</subject><subject>Social determinants</subject><subject>Stigma</subject><subject>Substance Abuse</subject><subject>Systematic review</subject><subject>Unprotected sex</subject><subject>Variables</subject><issn>1747-597X</issn><issn>1747-597X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ARHDP</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNUk1v1DAQjRCIlsIf4GSJE0IpduLYCQekagV0pSIQX-JmTZxJ4iWJt7azy9754Xi7VWElDtjyh-z33tgzL0meMnrOWCleepZTxlKa0ZTSnIqU3UtOmeQyLSr5_f5f-5PkkfcrSjmvqvJhcpJnZc4YlafJr48ONzDgpJHA1JDedD1xxv8gNfawMXZ2noD3VhsI2JCtCT25XHwjAX0wU0dgtHFeo10PSLa9JWZaoQ6kcXPnXxEgfucDjhCMJjGUwe1NnPcYIIUJhp03_nHyoIXB45Pb9Sz5-vbNl8VlevXh3XJxcZXqQvKQYs11m-layEY3reCCaai1YMAEB8GERtYyASUTWVHyTLS0QdHkkgJSWRdFfpYsD7qNhZVaOzOC2ykLRt0cWNcpcPGhA6qiFlUr4xBlwUuqa2h4mwGtda1ZJauo9fqgtZ7rERuNU3AwHIke30ymV53dKMl5UeU8Cjy7FXD2eo7ZVKuY7JgRrzLOORVZWdE_qC4WSZmptVFMj8ZrdSFyXuWxvHlEnf8DFXuDo9F2wtbE8yPC8yNCxAT8GTqYvVfLz5-OsdkBq5313mF790lG1d6I6mBEFY2oboyoWCS9OJC2WNvWa7N32B2RUloIyWhJ920fovx_9MKE6CY7Lew8hfw3Hx_wqA</recordid><startdate>20200824</startdate><enddate>20200824</enddate><creator>Karimi, Salah Eddin</creator><creator>Bayani, Azadeh</creator><creator>Higgs, Peter</creator><creator>Bayat, Amir-Hossein</creator><creator>Hemmat, Morteza</creator><creator>Ahounbar, Elahe</creator><creator>Armoon, Bahram</creator><creator>Fakhri, Yadolah</creator><general>Springer Nature</general><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>17B</scope><scope>ARHDP</scope><scope>BLEPL</scope><scope>DVR</scope><scope>EGQ</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>0-V</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AM</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGRYB</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K7.</scope><scope>K9.</scope><scope>M0O</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3564-1791</orcidid><orcidid>https://orcid.org/0000-0002-3579-7641</orcidid><orcidid>https://orcid.org/0000-0001-5467-9889</orcidid></search><sort><creationdate>20200824</creationdate><title>Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis</title><author>Karimi, Salah Eddin ; Bayani, Azadeh ; Higgs, Peter ; Bayat, Amir-Hossein ; Hemmat, Morteza ; Ahounbar, Elahe ; Armoon, Bahram ; Fakhri, Yadolah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c574t-eb4cf2cb67dcdf6461cabc61a164a616ce1f16a816258426f0de6d370ae07b553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Agreements</topic><topic>Confidence intervals</topic><topic>Criminalization</topic><topic>Drug use</topic><topic>Drugs</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Infections</topic><topic>Life Sciences & Biomedicine</topic><topic>Meta-analysis</topic><topic>Past treatment attempt</topic><topic>Previous testing</topic><topic>Review</topic><topic>Science & Technology</topic><topic>Sexual behavior</topic><topic>Social determinants</topic><topic>Stigma</topic><topic>Substance Abuse</topic><topic>Systematic review</topic><topic>Unprotected sex</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karimi, Salah Eddin</creatorcontrib><creatorcontrib>Bayani, Azadeh</creatorcontrib><creatorcontrib>Higgs, Peter</creatorcontrib><creatorcontrib>Bayat, Amir-Hossein</creatorcontrib><creatorcontrib>Hemmat, Morteza</creatorcontrib><creatorcontrib>Ahounbar, Elahe</creatorcontrib><creatorcontrib>Armoon, Bahram</creatorcontrib><creatorcontrib>Fakhri, Yadolah</creatorcontrib><collection>Web of Knowledge</collection><collection>Web of Science - Social Sciences Citation Index – 2020</collection><collection>Web of Science Core Collection</collection><collection>Social Sciences Citation Index</collection><collection>Web of Science Primary (SCIE, SSCI & AHCI)</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Criminal Justice Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Criminology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Criminal Justice (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Criminal Justice Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Substance abuse treatment, prevention and policy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karimi, Salah Eddin</au><au>Bayani, Azadeh</au><au>Higgs, Peter</au><au>Bayat, Amir-Hossein</au><au>Hemmat, Morteza</au><au>Ahounbar, Elahe</au><au>Armoon, Bahram</au><au>Fakhri, Yadolah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis</atitle><jtitle>Substance abuse treatment, prevention and policy</jtitle><stitle>SUBST ABUSE TREAT PR</stitle><date>2020-08-24</date><risdate>2020</risdate><volume>15</volume><issue>1</issue><spage>1</spage><epage>16</epage><pages>1-16</pages><artnum>64</artnum><issn>1747-597X</issn><eissn>1747-597X</eissn><abstract>Background Hepatitis C diagnosis could be a gateway to behavioral change and subsequent decline in transmission among people who inject drugs (PWIDs). We assessed the association between the social determinants of PWID, their risk behaviors and hepatitis C testing. Methods We searched for studies in English published before May 1, 2020, on PubMed, Scopus, Cochrane, and Web of Science to identify primary studies on the factors associated with hepatitis C virus (HCV) testing among PWID. After reviewing for study duplicates, the full-text of selected articles were assessed for eligibility using Population, Intervention, Comparator, Outcomes (PICO) criteria. i) population: individuals who report injecting drugs; ii) intervention: HCV testing in the past year; iii) comparator: PWIDs who did not have an HCV test; iv) outcome: HCV testing among PWIDs and v) study type: cross-sectional, cohort, and case-control studies. Two independent reviewers (author BA and AB) chose the references in a two-phased monitoring process. The authors gathered data from selected papers, including the surname of the first author, publication date, participant demographic data (age, sex, and level of education) and other characteristics like previous HCV testing, past treatment attempts, duration of injecting drug use and condomless sex. We used fixed and random-effects meta-analysis models to estimate the pooled prevalence, pooled odds ratio (OR), and 95% confidence intervals. The data were analyzed using Stata 12.0 software. Results After a detailed assessment of over 12,000 articles, a total of 16 studies containing 38,952 participants met the eligibility criteria. Our findings showed a pooled prevalence rate of 61.01% (95% CI, 34.65-84.32%) for recent HCV testing among PWIDs. Being female (OR = 1.69, 95%CI = 1.13, 2.26), aged > 30 years, (OR = 2.61, 95%CI = 1.66-3.56) having past treatment attempt (OR = 2.24, 95%CI = 1.80-2.68), and reporting a previous test (OR = 2.03, 95%CI = 1.23-2.82). were significantly associated with having a recent HCV test.,,. Finding of present study was that unprotected sex had a negative association with HCV testing. Those PWIDs who had unprotected sex were 0.56 times less likely to have completed HCV testing during last year (OR = 0.56, 95%CI = 0.33-0.78). Conclusion Prevention programs that address age > 30 years, being female, past treatment attempt, previous testing of safe sexual practices, are strongly recommended to prioritize HCV risk reduction strategies.</abstract><cop>LONDON</cop><pub>Springer Nature</pub><pmid>32831107</pmid><doi>10.1186/s13011-020-00306-1</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0003-3564-1791</orcidid><orcidid>https://orcid.org/0000-0002-3579-7641</orcidid><orcidid>https://orcid.org/0000-0001-5467-9889</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1747-597X |
ispartof | Substance abuse treatment, prevention and policy, 2020-08, Vol.15 (1), p.1-16, Article 64 |
issn | 1747-597X 1747-597X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7445934 |
source | DOAJ Directory of Open Access Journals; SpringerNature Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Web of Science - Social Sciences Citation Index – 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Springer Nature OA/Free Journals |
subjects | Agreements Confidence intervals Criminalization Drug use Drugs Hepatitis C Hepatitis C virus Infections Life Sciences & Biomedicine Meta-analysis Past treatment attempt Previous testing Review Science & Technology Sexual behavior Social determinants Stigma Substance Abuse Systematic review Unprotected sex Variables |
title | Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T04%3A02%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20and%20high%20risk%20behaviours%20associated%20with%20HCV%20testing%20among%20people%20who%20inject%20drugs:%20a%20systematic%20review%20and%20Meta-analysis&rft.jtitle=Substance%20abuse%20treatment,%20prevention%20and%20policy&rft.au=Karimi,%20Salah%20Eddin&rft.date=2020-08-24&rft.volume=15&rft.issue=1&rft.spage=1&rft.epage=16&rft.pages=1-16&rft.artnum=64&rft.issn=1747-597X&rft.eissn=1747-597X&rft_id=info:doi/10.1186/s13011-020-00306-1&rft_dat=%3Cgale_pubme%3EA634935973%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2444062890&rft_id=info:pmid/32831107&rft_galeid=A634935973&rft_doaj_id=oai_doaj_org_article_5b69f769f685480cbad4f2a0bcbc1979&rfr_iscdi=true |